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Beneficial effects of iron therapy in renal failure patients on (normal blood loss should be ,400 mg per year) due
hemodialysis. Iron deficiency is a common problem in patients to blood retention by the dialysis lines and filter [3].
treated with hemodialysis. If not detected and treated appropri- Additional sources of blood loss are related to bloodately, the effectiveness of recombinant human erythropoietin
sampling for laboratory testing, accidental bleeding fromtherapy is compromised. Much has been learned in recent years
the dialysis access, surgery, and occult gastrointestinalwith respect to iron therapy for hemodialysis patients. A series
of studies have clearly defined the efficacy of intravenous iron bleeding. The net effect is a marked reduction in the
compounds, and recently released clinical practice guidelines overall supply of iron. In addition to the reduction of
have set the appropriate clinical context for the use of these the body’s iron stores, there is also an increase in theagents. The purpose of this article is to examine the beneficial
demand for iron in patients treated with rHuEPO, whicheffects of iron replacement therapy for hemodialysis patients.
may lead to iron deficiency even if iron stores are not
fully depleted [4, 5]. This occurs because during the in-
tense stimulus to produce new red blood cells inducedRecombinant human erythropoietin (rHuEPO) has
by intravenous rHuEPO, the body is unable to optimallybeen available for the treatment of the anemia of end-
access even fairly normal iron stores [6]. Only approxi-stage renal failure in the United States since 1989. The
mately 3 mg of the body’s total iron supply of 3,000 toeffect has been a marked improvement in hematocrit
5,000 mg circulates in blood [7]. In the five to sevenvalues [1], and probably of the quality of life, lifespan,
hours of intense red cell production following intrave-and functional status of hundreds of thousands of dialysis
nous rHuEPO therapy [8], this small quantity of circulat-patients. It has been clear, however, that the maximal
ing iron is insufficient to match demand for iron by thepotential of the medication has not been reached. In the
erythron. Thus, among hemodialysis patients, the body’sfirst full year of clinical use in the United States, only
supply of iron is reduced, and the demand for iron is44% of patients experienced a hematocrit of greater than
increased, leading to the frequent development of iron30% [1]. In 1993 it was estimated that 43% of patients
deficiency. Therapy with iron is, therefore, vitally impor-still had a hematocrit below that value [2]. With the
tant for patients treated with hemodialysis.realization that anemia therapy in the United States has
Oral iron formulations are the simplest, most conve-not achieved optimal outcomes, there has been a rapidly
nient, and least expensive method for supplementinggrowing appreciation of the importance of iron manage-
iron. The most commonly used form in the United Statesment to improve the effectiveness of rHuEPO therapy.
is ferrous sulfate, which is usually dispensed as 325 mgThe purpose of this article is to review the subject of iron
tablets of which 20% is elemental iron. Table 1 is atherapy for hemodialysis patients treated with rHuEPO.
compilation of common forms of oral iron currentlyIron deficiency almost always occurs on the basis of
available. Several principles guide the therapeutic usechronic blood loss. In primary care, iron deficiency is
of oral iron for hemodialysis patients. First, 200 mg ofseen mostly in young women with heavy menstrual blood
elemental iron should be administered per day. Second,loss, and in older patients with gastrointestinal malignan-
the pills should be consumed between meals, since sev-cies which lead to chronic mucosal bleeding. Hemodialy-
eral chemicals present in food can markedly impair ironsis patients, similarly, become iron deficient primarily
absorption [9]. Finally, since iron is absorbed relativelydue to chronic blood loss. The hemodialysis procedure
proximally in the gastrointestinal tract, enteric coateditself leads to the lost of 1 to 2 grams of iron per year
formulations should in general be avoided.
There has been increasing recognition in recent years
Key words: anemia, dialysis, erythropoietin, iron replacement. that oral iron supplements may not be effective for the
majority of patients treated with hemodialysis. Recent 1999 by the International Society of Nephrology
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Table 1. Oral iron supplements tend out radially from this core solubilizing the molecule.
Other forms of intravenous iron have been used for yearsElemental Expected monthly
Tablet size iron wholesale cost among hemodialysis patients treated in other parts of
Generic ferrous sulfate 325 mg 65 mg $2.29 the world. Specifically in Europe, there has been a wealth
Iron polysaccharide 150 mg Unknown $7.12 of experience utilizing ferric gluconate and iron saccha-
Ferrous gluconate 325 mg 35 mg $5.08
rate, as well as iron dextran.Ferrous fumarate 325 mg 108 mg $1.63
After intravenous injection of iron dextran, the mole-Cost is in U.S. dollars.
cule is removed from plasma by macrophages of the
reticuloendothelial system with a half-life in plasma of
between 5.9 hours and three days [16, 17]. There is rapid
intracellular splitting of iron dextran, leading to a peakstudies have suggested that hemodialysis patients do not
absorb oral iron normally [10, 11]. Kooistra et al found in serum ferritin levels within two weeks of a therapeutic
course [18]. The drug is most commonly administeredthat iron absorption in iron deficient hemodialysis pa-
tients was 44% less efficient compared to iron deficient as a course of 1,000 mg divided over ten consecutive
hemodialysis treatments. We evaluated this regimen innormals [10]. A classic study by Eschbach, Cook and
Finch found that hemodialysis patients absorb almost no 28 hemodialysis patients with presumed iron deficiency
based on a serum ferritin , 100 ng/ml. There was airon from the diet until the serum ferritin concentration
drops to below 50 ng/ml, a value consistent with severe significant increase in mean hematocrit into the targeted
range, from 29.1% to 32.9%, with an accompanying re-iron deficiency in hemodialysis patients [12]. These data
suggest that hemodialysis patients probably do not ab- duction in rHuEPO dose requirements by 11%. An inter-
esting observation was that the majority of patients re-sorb any significant amount of iron provided by oral iron
supplements. It is, therefore, unlikely that oral iron could mained somewhat iron deficient after the course of
intravenous iron. After 10 weeks of observation, 71%deliver enough iron to keep up with the relentless ongo-
ing blood loss hemodialysis patients experience. In addi- of patients had serum ferritin levels that again dropped
below 100 ng/ml. A serum ferritin concentration of ,28tion to problems with the absorption of oral iron, poor
patient compliance is probably a superimposed second- ng/ml at baseline predicted all patients who would be
underdosed with iron using this popular dosing regimenary barrier to effectiveness. Gastrointestinal side effects
are common with oral iron, which may be caused by the [19]. These data suggest that the degree of iron deficit
in these patients was likely greater than 1,000 mg, orproduction of reactive oxygen species in the gut [13].
Typical symptoms include constipation, dyspepsia, diar- that ongoing losses of iron in the 10-week follow-up
were greater than expected. In a similar study, Sunder-rhea, and bloating [14]. Other factors contributing to
poor compliance with oral iron supplements include in- Plassman and Ho¨rl administered iron saccharate 1,000
mg intravenously over ten consecutive hemodialysisconvenience and nonreimbursed cost.
In a study reported in 1995 by Wingard et al, 46 hemo- treatments to patients with suspected iron deficiency.
Patients received repeated courses of treatment asdialysis patients were randomized to one of four oral
iron treatment groups [15]. Patients were followed for a needed to correct the iron deficiency. The mean hemo-
globin increased from 9.4 g/dl to 11.1 g/dl with a reduc-prospective six-month period, with intensive monitoring
of patients’ compliance with oral iron. At the completion tion of rHuEPO dose requirements from 217 m/kg/week
to 63 m/kg/week [20]. Taken together, these studies sup-of follow-up, mean hematocrit values remained below
30% in three of four treatment groups. Similarly, the port the efficacy of intravenous iron therapy for iron
deficient hemodialysis patients. It is clearly not sufficient,transferrin saturation remained below 20% in three of
four treatment groups, and there was a trend to reduced however, to treat with 1,000 mg of either iron therapy
without rechecking the effect on iron status, given theserum ferritin concentrations [15]. This study suggests
that even in the best case scenario of intensive support likelihood that many patients require more than 1,000
mg to correct their iron deficiency. We recommend re-of drug compliance, oral iron is not likely to maintain
long-term iron balance. Much of our understanding of testing the serum ferritin two weeks after completion of
a therapeutic course, and retreating if it is still belowthe lack of effectiveness of oral iron therapy comes from
studies comparing oral iron to intravenous iron supple- 100 ng/ml.
Recently the term “maintenance intravenous iron ther-ments. These studies will be discussed in the following
section. apy” has been used increasingly. In essence it refers to
using small doses of intravenous iron on a regular ongo-In the United States only one form of intravenous iron
has been available for clinical use, iron dextran. This ing basis to maintain iron balance. Macdougall et al ran-
domized 31 patients to either no iron treatment, oralmolecule compartmentalizes iron in a dense central core
of ferricoxyhydroxide (the same iron core found in ferri- iron therapy (ferrous sulfate 200 mg tid), or intravenous
iron dextran therapy (125 mg per week) at the initiationtin). Dextran chains, which are polymers of glucose, ex-
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Table 2. Studies of maintenance iron therapy for hemodialysis patients
Study Dose Follow-up months Result
Macdougall et al [21] Iron dextran 125 mg/week 6 63% improvement in hematocrit
Fishbane et al [22] Iron dextran 200 mg/week 4 46% reduction in rHuEPO dose
Senger and Weiss [23] Iron dextran various doses 6 75% reduction in rHuEPO dose
Sunder-Plassman and Ho¨rl [20] Iron saccharate 30–120 mg/week 6 40% reduction of rHuEPO dose
Taylor et al [25] Ferric gluconate 62.5 mg biw 6 33% reduction of rHuEPO dose
Schaefer and Schaefer [24] Ferric gluconate 40 mg/week 6 43% reduction in rHuEPO dose
of rHuEPO therapy. After four months of follow-up travenous iron dextran were challenged with ferric gluco-
nate. None of the patients experienced an adverse reac-intravenous iron was the most effective therapy for im-
proving mean hemoglobin, from 7.3 g/dl to 11.9 g/dl. tion, suggesting that this agent is safe in patients
previously found to be allergic to iron dextran [30]. Con-Interestingly, there was no difference in efficacy between
the oral iron and no iron groups [21]. Our group random- cern has been raised with regard to early release of iron
by ferric gluconate. Physical chemical studies have sug-ized 75 patients to treatment with either oral iron or
intravenous iron dextran 200 mg/week. After four gested that ferric gluconate does not bind iron as avidly
as iron dextran [31]. Zanen et al found that rapid infu-months of follow-up, patients treated with intravenous
iron had 5.8% higher hematocrits, and a 46% mean re- sions of ferric gluconate resulted in greater than 100%
saturation of transferrin [32]. The clinical significance ofduction in the rHuEPO dose requirement. The dose used
was probably excessive, however, as the mean serum this observation is unclear, as ferric gluconate has been
used in Europe for many years with an anecdotal reputa-ferritin concentration increased to 754 ng/ml [22]. Senger
and Weiss found a 6% increase in hematocrit and a 75% tion for good safety. It is likely that this aspect of ferric
gluconate is more of academic interest than clinical im-reduction in rHuEPO requirements after six months of
iron dextran at 25 to 50 mg per week [23]. Schaefer and portance.
A novel method for intravenous iron treatment is ad-Schaefer achieved a 43% reduction of rHuEPO dose by
administering 40 mg of intravenous ferric gluconate per ministration by total dose infusion (administering the
entire therapeutic dose at one time). Recently, Auerbachweek [24]. Sunder-Plassman and Ho¨rl studied iron sac-
charate at a dose of 30 to 120 mg per week and achieved et al randomized 43 hemodialysis patients to receive
iron dextran as total dose infusion, 500 mg sequentiala 40% long-term reduction in the mean rHuEPO dose
[20]. Taylor et al treated 46 hemodialysis patients with infusions until the total dose was reached, or 100 mg
sequential infusions to total dose [33]. The total dose62.5 mg biw of ferric gluconate, which resulted in a 33%
reduction in rHuEPO requirements after six months [25]. was administered in 500 ml of 0.9% saline over two
hours. At the conclusion of study, the total dose infusionSepandj treated hemodialysis patients with 50 mg weekly
of iron saccharate for six months, resulting in a 14% was found to be as effective as divided dose infusions,
and less expensive to administer [33].increase in mean hematocrit and 34% reduction of mean
rHuEPO dose [26]. Taken together, the results of these Given all that has been learned regarding various
forms of iron therapy for hemodialysis patients in thestudies provide firm evidence demonstrating the marked
efficacy of chronic dosing with intravenous iron com- past several years, how do we synthesize a rational ap-
proach to therapy? The recently completed NKF-DOQIpounds (Table 2).
Intravenous iron dextran therapy is associated with a Guidelines for anemia management provided several
recommendations that provide standards of care specificsmall but important risk for allergic reactions (discussed
elsewhere in this issue). The incidence of such reactions for iron therapy [34]. The first states that the transferrin
saturation should be maintained at greater than 20%,is on the order of 6 to 7 in 1,000 patients treated [27,
28]. Because of these reactions, there has been interest and the serum ferritin greater than 100 ng/ml. In patients
in whom iron indices are not abnormal by these criteria,in evaluating other intravenous iron compounds for use
in the United States. Two recent studies utilizing ferric yet who still have hematocrit values of ,33 to 36%, a
course of intravenous iron should be used, and the re-gluconate indicate that this may be the next agent avail-
able in this country. In one study 46 iron deficient hemo- sponse evaluated. Importantly, the tests of iron status
should not be performed within a two-week window pe-dialysis patients were treated with 1,000 mg of intrave-
nous ferric gluconate over eight hemodialysis treatments. riod after a dose of intravenous iron. The group estimated
that the weekly required intravenous iron dose for pa-At day 47 of follow-up there was a 13.7% increase in
hematocrit, and a 61.6% increase in serum ferritin [29]. tients on maintenance therapy would be 25 to 100 mg per
week. With regard to the issue of potentially overusingIn a second study, nine patients who had previously
experienced an allergic reaction after treatment with in- intravenous iron, the guidelines recommend that pa-
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13. Schneider W: The fate of iron compounds in the gastrointestinaltients’ transferrin saturation should not be allowed to
tract. Arzneimittelforschung 37:92–95, 1987increase to greater than 50%, and the serum ferritin 14. Hallberg L, Ryttinger L, Solvell L: Side effects of oral iron
not greater than 800 ng/ml to minimize the risk of iron therapy. A double-blind study of different iron compounds in tablet
form. Acta Med Scand Suppl 459:3–10, 1966overload. Finally, when oral iron is used, the recommen-
15. Wingard RL, Parker RA, Ismail N, Hakim RM: Efficacy of oraldation is to provide 200 mg per day of elemental iron
iron therapy in patients receiving recombinant human erythropoie-
in two to three divided doses, preferably between meals. tin. Am J Kidney Dis 25:433–439, 1995
In conclusion, there has been a great surge of interest 16. Kamakakom K, Cavill I, Jacobs A: The metabolism of intrave-
nously administered iron dextran. Br J Haematol 25:637–643, 1973in iron therapy for hemodialysis patients in recent years.
17. Wood JK, Milner PFA, Pathak UN: The metabolism of iron-It has become clear that the initial suboptimal results
dextran given as a total dose infusion to iron deficient Jamaican
with respect to anemia outcomes in the United States subjects. Br J Haematol 14:119–129, 1968
18. Vercammen M, Goedhuys W, Boeyckens A, De Roy R, Senne-were at least partially due to a lack of attention to the
sael J, Sevens S, Gorus F: Iron and total iron binding capacityimportance of iron therapy to successful rHuEPO ther-
in serum of patients receiving iron-dextran: Kodak Ektachemapy. This is supported by 1993 USRDS data showing methodologies, spectrophotometry, and atom absorption spec-
that 50% of hemodialysis patients had a transferrin satu- trometry compared. Clin Chem 36:1812–1815, 1990
19. Fishbane S, Lynn RI: The efficacy of iron dextran for the treatmentration , 20%, 25% had a transferrin saturation , 10%,
of iron deficiency in hemodialysis patients. Clin Nephrol 44:238–and 56% had a serum ferritin of ,200 ng/ml. Clearly, iron
240, 1995
deficiency was epidemic among American hemodialysis 20. Sunder-Plassman G, Ho¨rl WH: Importance of iron supply for
patients. Initial data suggest that there has been some erythropoietin therapy. Nephrol Dial Transplant 10:2070–2076,
1995improvement recently, perhaps mirroring the increased
21. Macdougall IC, Tucker B, Thompson J, Baker LRI, Raine AEG:recognition of the importance of iron therapy. Future
A randomised controlled study of iron supplementation in patients
studies should lead to refinements and improvement in treated with erythropoietin. (abstract) J Am Soc Nephrol 4:428,
methods of iron replacement. 1993
22. Fishbane S, Frei GL, Maesaka J: Reduction of recombinant hu-
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